Point72 Asset Management
LXRX icon

Point72 Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Point72 Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.2M Buy
7,814,606
+7,530,581
+2,651% +$11M 0.02% 1111
2025
Q4 		$327K Buy
+284,025
New +$390K ﹤0.01% 3443
2025
Q1 		– Sell
-8,988,421
Closed -$6.64M – 2326
2024
Q4 		$6.64M Buy
8,988,421
+7,758,371
+631% +$9.35M 0.01% 856
2024
Q3 		$1.93M Sell
1,230,050
-2,891,141
-70% -$5.15M ﹤0.01% 1208
2024
Q2 		$6.92M Buy
4,121,191
+3,536,805
+605% +$6.34M 0.02% 745
2024
Q1 		$1.4M Buy
+584,386
New +$1.26M ﹤0.01% 1377
2023
Q2 		– Sell
-516,367
Closed -$1.25M – 2519
2023
Q1 		$1.25M Sell
516,367
-827,764
-62% -$1.9M ﹤0.01% 1066
2022
Q4 		$2.57M Sell
1,344,131
-2,269,369
-63% -$4.83M 0.01% 892
2022
Q3 		$8.67M Buy
+3,613,500
New +$10M 0.03% 546
2019
Q4 		– Sell
-528,100
Closed -$1.59M – 1120
2019
Q3 		$1.59M Buy
+528,100
New +$1.64M 0.01% 622
2017
Q2 		– Sell
-382,500
Closed -$5.49M – 933
2017
Q1 		$5.49M Buy
+382,500
New +$5.68M 0.03% 509

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management's LXRX Position: Q1 2026 in Review

Point72 Asset Management increased its Lexicon Pharmaceuticals (LXRX) stake by 2,651% in Q1 2026, buying an estimated $11M and bringing the position to 7,814,606 shares worth $12.2M. The position accounts for 0.02% of the portfolio, ranked #1111.

Point72 Asset Management first reported a position in LXRX in Q1 2017 and has held it in 11 quarters since. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Point72 Asset Management held 7,814,606 shares of Lexicon Pharmaceuticals worth $12.2M as of Q1 2026.
  • Point72 Asset Management bought 7,530,581 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $11M.
  • Lexicon Pharmaceuticals made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #1111 holding.
  • Point72 Asset Management first reported a position in Lexicon Pharmaceuticals in Q1 2017 and has held it in 11 quarters since.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.